- Home
- GUG vs FULC Comparison
GUG vs FULC Comparison
Compare GUG & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUG
- FULC
- Stock Information
- Founded
- GUG 2021
- FULC 2015
- Country
- GUG United States
- FULC United States
- Employees
- GUG N/A
- FULC N/A
- Industry
- GUG Trusts Except Educational Religious and Charitable
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- GUG Finance
- FULC Health Care
- Exchange
- GUG Nasdaq
- FULC Nasdaq
- Market Cap
- GUG 524.4M
- FULC 469.0M
- IPO Year
- GUG N/A
- FULC 2019
- Fundamental
- Price
- GUG $15.78
- FULC $9.15
- Analyst Decision
- GUG
- FULC Buy
- Analyst Count
- GUG 0
- FULC 7
- Target Price
- GUG N/A
- FULC $9.14
- AVG Volume (30 Days)
- GUG 108.9K
- FULC 426.7K
- Earning Date
- GUG 01-01-0001
- FULC 10-29-2025
- Dividend Yield
- GUG 9.67%
- FULC N/A
- EPS Growth
- GUG N/A
- FULC N/A
- EPS
- GUG N/A
- FULC N/A
- Revenue
- GUG N/A
- FULC N/A
- Revenue This Year
- GUG N/A
- FULC N/A
- Revenue Next Year
- GUG N/A
- FULC N/A
- P/E Ratio
- GUG N/A
- FULC N/A
- Revenue Growth
- GUG N/A
- FULC 2752.05
- 52 Week Low
- GUG $12.71
- FULC $2.32
- 52 Week High
- GUG $15.06
- FULC $9.89
- Technical
- Relative Strength Index (RSI)
- GUG 48.94
- FULC 54.35
- Support Level
- GUG $15.42
- FULC $8.89
- Resistance Level
- GUG $15.83
- FULC $9.84
- Average True Range (ATR)
- GUG 0.27
- FULC 0.58
- MACD
- GUG -0.02
- FULC -0.09
- Stochastic Oscillator
- GUG 41.48
- FULC 47.57
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.